The emergence of microalbuminuria following conditioning chemotherapy may predict the development of renal dysfunction. To confirm this, a 1-year retrospective cohort study was conducted in 31 myeloablative allogeneic SCT patients who received five consecutive measurements of albuminuria before conditioning therapy and on days 0, 7, 14 and 28 following SCT. The cohort had neither microalbuminuria nor renal dysfunction at baseline. Microalbuminuria was defined as an albumin-creatinine (Cr) ratio over 30 mg/g, and renal dysfunction was as an estimated glomerular filtration rate o60 mL/min per 1.73 m 2 . Cumulative incidence of renal dysfunction over time was analyzed by the Kaplan-Meier method. Multivariate Cox proportional hazards analysis was used to examine an association of de novo microalbuminuria with the incidence of renal dysfunction. In all, 16 patients (52%) developed microalbuminuria that was positive at least two times among the four measurements after SCT. The actuarial occurrence of chronic kidney disease was significantly higher in patients who developed microalbuminuria than in those who did not. Incidence of microalbuminuria had a significant risk of subsequent renal dysfunction (hazard ratio (95% confidence interval), 7.3 (1.2-140)). In conclusion, de novo microalbuminuria following conditioning therapy is a warning of near-term loss of renal function.
INTRODUCTION
Hematopoietic SCT has contributed to radical cure of hematological malignancies, and thus, the long-term survival of patients affected by these diseases. In contrast, SCT, especially myeloablative allogeneic (m-allo)-SCT, may involve a great risk of chronic kidney disease (CKD) in individuals undergoing successful SCT. 1, 2 Recent studies showed that CKD developed in 17% in 2-3 years 1 and 34% in 10 years 2 following m-allo-SCT, respectively, whereas CKD was observed in 9.4% of the general population in a mean follow-up of 18.5 years. 3 In general, CKD is increasingly recognized as a global public health problem. Outcomes of CKD include progression to endstage renal disease, complications of reduced kidney function and increased risk of other chronic diseases, such as cardiovascular disease and cancers. 4 Patients with CKD are more likely to die than to develop kidney failure. Thus, SCT survivors who have CKD may have a greater risk of death, cardiovascular disease events and hospitalization. Also, patients with end-stage renal disease associated with SCT may have higher morbidity and mortality than those due to other causes. 5 Accordingly, identification of incipient kidney disease after SCT is highly important not only for preventing progression to CKD and end-stage renal disease but also for improving overall outcomes in patients after successful SCT.
Microalbuminuria has been shown to be a reliable measure for subclinical kidney disease, 6 and a significant predictor for CKD, cardiovascular disease and mortality in the general population. 7 However, clinical significance of the development of microalbuminuria following SCT has not been fully examined. The objectives of this study were (i) to study the incidence and degree of microalbuminuria over time during 1 month after the implementation of m-allo-SCT and (ii) to assess whether de novo microalbuminuria is a new risk of evolution to loss in kidney function in the setting of m-allo-SCT.
MATERIALS AND METHODS

Study design
This study was a retrospective cohort study with the aim of ascertaining the relationships between the new onset of microalbuminuria and subsequent renal dysfunction in a 1-year follow-up period. Written informed consent was obtained from all participants before initiating conditioning therapy for SCT. The study was performed in accordance with the Declaration of Helsinki and was approved by the institutional committee on research ethics.
Study subjects
In all, 82 patients received m-allo-SCT between February of 2009 and October of 2010 at Tokyo Metropolitan Komagome Hospital. Among them, 31 participants were eligible for the study, as they had received five consecutive urinary albumin measurements before conditioning therapy (baseline) and on days 0 (day of SCT), 7, 14 and 28, and met the following four inclusion criteria: (1) age over 18 years; (2) absence of renal dysfunction at baseline, defined as estimated glomerular filtration rate (eGFR) o60 mL/min per 1.73 m 2 ; (3) absence of microalbuminuria at baseline, defined as urinary albumin-Cr ratio (ACR) 430 mg/g; and (4) surviving over 1 month after SCT.
6 h between the two daily fractions), and the major one consisted of BU (12.8 mg/kg for 4 days) and CY (120 mg/kg for 2 days). In addition, selective kidney shielding blocks were routinely used during TBI and this reduced the renal dose to 10 Gy. 8 The patients were given i.v. infusion of donor hematopoietic cell derived from BM, cord blood or peripheral blood on day 0. All patients received acute GVHD prophylaxis with CYA or tacrolimus (FK), and additionally short-term MTX (10 mg/m 2 per day on day 1 and 7 mg/m 2 per day on days 3, 6 and 11). CYA was started on day À 1 at 3 mg/kg per day with continuous i.v. infusion, and similarly, FK at 0.03 mg/ kg per day with continuous i.v. infusion. Serum concentrations of CYA and FK were targeted at 200-300 and 10-20 ng/mL, respectively. The dosage of both drugs was adjusted according to renal function and the degree of acute GVHD. Prophylactic anti-microbial therapy usually included tosufloxacin (300 mg per day), fluconazole (100 mg per day), trimethoprimsulfamethoxazole (trimethoprim 240 mg and sulfamethoxazole 1200 mg; 3 times per week) and acyclovir (250 mg per day). Ganciclovir was used two times daily if CMV antigenemia was positive.
Samples and measurements
Urine samples were collected consecutively in the morning fasting state, quickly centrifuged at 2000 r.p.m. for 5 min at 4 1C, and stored at À 80 1C until analysis. Because of compensation for differences in the urine flow rate, 9 the urinary albumin concentration was corrected by the urine Cr concentration. Serum Cr was measured every 2 or 3 days during the hospital stay and once or two times per month over 1 year after discharge. Urinary albumin was measured using a turbidimetric immunoassay (N-assay TIA Micro Alb; Nittobo Medical Co., Tokyo, Japan), and urinary and serum Cr were measured using an enzyme assay (IATRO LQ CRE (A) II; Mitsubishi Chemical Medicine Co., Tokyo, Japan).
Definition of clinical variables
Microalbuminuria and renal dysfunction were defined as ACR X30 mg/g and as eGFR o60 mL/min per 1.73 m 2 , respectively. eGFR based on serum Cr was calculated using the three-variable Japanese equation developed by the Japanese Society of Nephrology (eGFR (mL/min per 1.73 m
. 10 Post-SCT microalbuminuria was defined as microalbuminuria that was positive at least two times in the four measurements between days 0 and 28. Post-SCT renal dysfunction was defined as a sustained decrease in eGFR o60 mL/min per 1.73 m 2 after day 28 in at least three consecutive measurements. The diagnosis of acute GVHD was based on previously published criteria. 11 Hypertension was defined as systolic blood pressure of X140 mm Hg and/or diastolic blood pressure of X90 mm Hg, or the use of antihypertensive agents at baseline. Diabetes mellitus was defined as a diagnosis of diabetes mellitus before baseline, or the use of oral antidiabetic agents or insulin at baseline.
Statistical analyses
Data are shown as the mean ± s.d., unless otherwise indicated. Comparisons between two groups were performed using the Mann-Whitney U-test for continuous variables and the Fisher's exact test for categorical variables. The Wilcoxon's signed-rank test was used for analysis between paired variables. Cumulative curves of incident renal dysfunction were prepared by the Kaplan-Meier method and the log-rank test was used to analyze differences between the curves. Multivariate Cox proportional hazards regression analysis was used to evaluate an association of the emergence of post-SCT microalbuminuria and development of post-SCT renal dysfunction. The hazard ratio was calculated with its 95% confidence interval (CI). The following variables were assessed as confounders, as some were relevant to the incidence of renal dysfunction on a clinical and literature basis: age, gender, presence of hypertension, baseline ACR and eGFR, exposure to TBI, use of CYA and incidence of acute GVHD Xgrade 2 after SCT. 1, 5, 12 Variables with Po0.10 in univariate analyses were incorporated into the multivariate model. Po0.05 was considered significant. All statistical analyses were performed using JMP ver. 9.0 (SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics of patients who developed post-SCT microalbuminuria and those who did not Demographics and clinical data at baseline are shown in Table 1 . Mean age of the participants was 45.5±12.1 years old. Mean eGFR and ACR were 95.5 ± 21.4 mL/min per 1.73 m 2 and 8.30 ± 7.21 mg/ g, respectively. In all, 16 (52%) were men. Three patients had hypertension, and none had diabetes mellitus. The underlying lymphohematological diseases were AML (n ¼ 13), myelodysplastic syndrome (n ¼ 8), ALL (n ¼ 5), severe aplastic anemia (n ¼ 2), CML (n ¼ 1), multiple myeloma (n ¼ 1) and non-Hodgkin's lymphoma (n ¼ 1). Sources of stem cell included related BM (n ¼ 1), unrelated BM (n ¼ 25), cord blood (n ¼ 3) and peripheral blood (n ¼ 2). In all, 29 patients (93.5%) received first SCT (no prior SCT), and the others a second SCT. In all, 10 (32%) were transplanted on disease. A myeloablative conditioning regimen, including TBI, was applied to 14 patients (45.2%), and CYA for GVHD prophylaxis was administered to 10 patients (32.3%). Age significantly differed between patients who developed post-SCT microalbuminuria and those who did not (50.2±10.0 vs 40.5 ± 12.5 years, P ¼ 0.0242). No other variables showed significant differences between the two patient groups.
Incidence and degree of post-SCT microalbuminuria over time following SCT The frequency and degree of microalbuminuria at each time point is shown in Figure 1 , and varied among time point: 0% before conditioning therapy (baseline), 48.4% on day 0 (at SCT), 54.8% on day 7, 41.9% on day 14 and 45.2% on day 28. ACR was 8.30 ± 7.21 mg/g at baseline, 77.1 ± 97.2 mg/g at SCT (on day 0), 72.2±152.9 mg/g on day 7, 48.6±70.1 mg/g on day 14 and 139 ± 405.8 mg/g on day 28. Of 31 patients, 16 (51.6%) developed post-SCT microalbuminuria, defined as one that was positive at least two times in the four measurements between days 0 and 28. The eGFRs in these patients developing post-SCT microalbuminuria changed from 89.3 ± 18.5 (baseline) to 74.5 ± 24.8 mL/min per 1.73 m 2 (day 28) during the period, but there was no significant difference between them (P ¼ 0.0502). The likelihood of the occurrence of post-SCT renal dysfunction significantly differed between the presence and absence of post-SCT microalbuminuria (P ¼ 0.0017). Of those who developed post-SCT renal dysfunction (n ¼ 11), seven (63.6%) died after the development of renal dysfunction in the follow-up period. On the other hand, of those who did not develop post-SCT renal dysfunction (n ¼ 20), one (5%) died before the development of renal dysfunction and three moved to local hospitals without our follow-up.
Factors associated with the development of post-SCT renal dysfunction Factors associated with the development of post-SCT renal dysfunction are shown in Table 2 . According to the results of the univariate analysis, age and ACR at baseline were incorporated into the multivariate model. Incidence of post-SCT microalbuminuria was the only statistically significant factor for the development of post-SCT renal dysfunction (HR 7.31; 95% CI 1.23-140; P ¼ 0.0265).
DISCUSSION
This longitudinal study showed that post-SCT microalbuminuria developed in approximately 50% of the patients following conditioning therapy for SCT, and that this incipient urinary abnormality was predictive of a near-term decrease in glomerular function. The emergence of de novo microalbuminuria might represent a wide spectrum of renal structural and functional impairment that accompanies SCT procedures. Timing of the appearance indicates that the emergence of de novo microalbuminuria is caused by something included in the conditioning procedures. The use of a high dose of CY and subsequent burden of calcinurin inhibitors and MTX, which are common to both m-allo conditioning regimens, are most likely involved. According to previous studies, CY and MTX induce glomerular injury as well as tubular damage, 12, 13 which may lead to urinary albumin excretion. Calcineurin inhibitors, such as CYA and FK, may induce microalbuminuria indirectly through acute tubular injury, 14 as Russo et al. 15 have shown that proximal tubular damage changes the tubular reabsorption of albumin excreted through glomeruli in uremic rat models. In addition, the systemic inflammatory state, activated cytokine cascades and hypercoagulability, which may accompany the death of leukemic cells, acute GVHD and engraftment syndrome in the early phase of SCT may, in part, contribute to persistence of microalbuminuria after 2-3 weeks of SCT both substantially and functionally. [16] [17] [18] This study showed that de novo microalbuminuria within 1 month after the conditioning therapy may predict the development of renal dysfunction within 1 year after SCT in the m-allo-SCT. Numerous studies showed that microalbuminuria was a predictor of mortality and the development of CKD in the general and several pathological populations. 6, 7, [19] [20] [21] [22] Moreover, the 2009 KGIDO risk category classification has emphasized the importance of albuminuria as an independent risk for developing a decrease in eGFR in the general population. 23 As for SCT patients, there is only one report by Hingorani et al., 24 which showed the increasing incidence of albuminuria over time after SCT and the relationship of albuminuria with poor outcomes. The incidence of albuminuria was 37% at baseline, 76% on day 35 and 64% on day 100 after SCT, respectively, in their study. They also showed the significant association between the presence of albuminuria at day 100 and the development of CKD or non-relapse mortality within 1 year after SCT. Unfortunately, their results were not appropriate for comparison with ours, partly because their study was based on urinary data that were collected at later time points than ours, and included patients with albuminuria at baseline and those receiving non-myeloablative regimens (26%), which usually target elderly patients with several comorbidities. Nevertheless, their results may be helpful to strengthen the likelihood that albuminuria emerges in high frequency and increases after SCT, and that it is closely associated with the development of renal dysfunction.
Our result suggested that de novo post-SCT microalbuminuria is a harbinger of later development of CKD in SCT patients. Its occurrence might offer a chance to intervene in those subjects who have it or to attempt to mitigate the later development of CKD. Angiotensin-converting enzyme inhibitor was reported to reduce urinary albumin excretion and a subsequent decline in renal function in the general population. 25 In the setting of SCT, Cohen et al. 26 have shown that use of angiotensin-converting enzyme inhibitor has a potential to attenuate the development of CKD in patients after radiation-based SCT in the absence of adverse effects on hematological outcome. Accordingly, use of angiotensinconverting enzyme inhibitor might be considered as a treatment tool to mitigate the later development of CKD, especially in subjects who manifest microalbuminuria following SCT.
This study has several limitations. First, pathological examination of kidney tissues was not performed in patients developing de novo microalbuminuria, as it is generally not feasible to conduct a renal biopsy due to the perceived risks of the procedure in the early phase before stem cell engraftment; therefore, it has not yet been determined whether the major cause of post-SCT microalbuminuria is renal structural or functional impairment in nature. Second, the sample size was homogeneous yet very small, as we attempted to see the impact of SCT procedures on kidney disease in a cohort limited to subjects receiving m-allo procedures, with neither microalbuminuria nor a decrease in renal function at baseline. This may be associated with the high hazard ratio and the wide 95% CI for microalbuminuria in the multivariate Cox analysis. It is therefore warranted to validate the results in a large external SCT cohort. Third, the development of CKD was progressive after the SCT, which strongly indicates that incident microalbuminuria post-SCT was sustained during the whole follow-up period; however, the measurements of albuminuria were limited to the five time points before and after SCT because of ethical restrictions, and were not performed in all participants after day 28 of SCT, partly because they were followed up by hematologists who are usually not interested in urinalysis at their routine examinations. Finally, body weight loss in SCT patients possibly contributed to the inaccuracy of Cr-based eGFR; however, it was unclear as to how much body weight loss (muscle wasting) was for each individual, as we could not measure each body weight at the time of CKD incidence.
In conclusion, de novo microalbuminuria occurs in approximately 50% of m-allo-SCT patients after conditioning therapy. Such microalbuminuria is likely to be a simple sign of a near-term decrease in renal function in SCT recipients. 
